MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020
(World News Science)

MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020 MGD019 well-tolerated with early signals of activity in advanced solid tumors not typically responsive to checkpoint inhibition Recommended Phase 2 dose established for MSS CRC, NSCLC expansion cohorts Presentation is available on-demand as part of the ESMO Virtual Congress 2020 ROCKVILLE, MD, Sept. 20, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced clinical data from the dose escalation portion of a Phase 1 clinical...